30
Participants
Start Date
April 30, 2023
Primary Completion Date
April 30, 2024
Study Completion Date
June 30, 2026
Radiotherapy
95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.
Toripalimab
Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
The Central Hospital of Lishui City
OTHER